Efficient ovalbumin delivery using a novel multifunctional micellar platform for targeted melanoma immunotherapy
File(s)
Author(s)
Type
Journal Article
Abstract
Cancer immunotherapy is considered to be one of the alternatives to traditional chemotherapy. It's known that foreign antigen, such as ovalbumin (OVA), can label tumor cells, leading to neoantigen recognition by cytotoxic T lymphocytes. Herein, a novel multifunctional micelle coated with PEGylated hyaluronic acid (HA) was prepared through self-assembly and electrostatic interaction. The OVA-loaded micelle with uniform size (132.1 ± 0.2 nm in diameter) exhibited favorable stability and sustained release profiles. The HA-coated micelle could target CD44-overexpressed cells and enhance the cellular uptake of OVA by 11.9 fold compared to free OVA. In vitro studies revealed that the cationic polymer, polyethyleneimine, could facilitate endosomal escape of OVA to label a tumor cell. After treatment with the OVA-loaded micelle, tumor growth in mice was significantly inhibited by 70% compared to the group treated with free OVA. All these results suggest the potential application of the immunotherapeutic micellar platform for melanoma treatment.
Date Issued
2019-04
Date Acceptance
2019-01-10
Citation
International Journal of Pharmaceutics, 2019, 560, pp.1-10
ISSN
0378-5173
Publisher
Elsevier
Start Page
1
End Page
10
Journal / Book Title
International Journal of Pharmaceutics
Volume
560
Copyright Statement
© 2019 Elsevier B.V. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/30677484
PII: S0378-5173(19)30062-6
Subjects
Immunotherapy
Melanoma
Multifunctional micelle
Ovalbumin
Self-assembly
Publication Status
Published
Coverage Spatial
Netherlands
Date Publish Online
2019-01-21